Revenue: As of FY2025 Q1, the actual value is USD 579.66 K.

EPS: As of FY2025 Q1, the actual value is USD -0.17.

EBIT: As of FY2025 Q1, the actual value is USD -1.038 M.

Segment Revenue

• Patient Care Services: Revenue decreased to $570,936 for the three months ended March 31, 2025, from $785,843 for the same period in 2024.
• Product Retail Sales: Revenue decreased significantly to $823 for the three months ended March 31, 2025, from $43,186 for the same period in 2024.
• Service Affiliate Agreements: Revenue was $7,896 for the three months ended March 31, 2025, with no comparable revenue in 2024.

Operational Metrics

• Net Loss: The net loss increased to - $1,038,011 for the three months ended March 31, 2025, compared to - $282,326 for the same period in 2024.
• Operating Expenses: Total operating expenses increased to $1,621,396 for the three months ended March 31, 2025, from $1,066,156 for the same period in 2024.
• Salaries and Wages: Increased by $295,211, or 41.7%, to $1,003,177 for the three months ended March 31, 2025.
• General and Administrative Expenses: Increased by $302,309, or 104.2%, to $592,437 for the three months ended March 31, 2025.

Cash Flow

• Net Cash Used in Operating Activities: - $865,083 for the three months ended March 31, 2025, compared to - $213,439 for the same period in 2024.
• Net Cash Used in Investing Activities: - $173,448 for the three months ended March 31, 2025, compared to - $11,182 for the same period in 2024.
• Net Cash Used in Financing Activities: - $94,519 for the three months ended March 31, 2025, compared to - $13,496 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Kindly MD aims to increase cash reserves and liquidity through strategic transactions and optimize revenue by increasing sales, improving margins, and controlling ongoing operating expenses.
• Non-Core Business: No specific plans related to divestitures or emerging segments were mentioned.

Unique Metrics

• Insurance Reimbursements: The company earned $85,273 in reimbursements from insurance payers during the three months ended March 31, 2025, a 145.6% increase from the $34,772 earned during the same period in 2024.